Evocalcet

Evocalcet is a potent, orally active calcium-sensing receptor agonist under clinical development for hyperparathyroidism. By activating the CaSR on parathyroid gland cells, Evocalcet suppresses the secretion of parathyroid hormone, reducing serum PTH and calcium levels. This targeted mechanism of Evocalcet provides a rational therapeutic approach for secondary hyperparathyroidism in chronic kidney disease patients. In vivo studies have demonstrated that Evocalcet (0.3 mg/kg, oral, once daily for 5 weeks) effectively decreases serum PTH and calcium levels while increasing serum inorganic phosphorus in CKD rat models. The clinical development of Evocalcet has progressed through Phase 3 trials, supporting its potential as a novel therapeutic option for mineral and bone disorders associated with chronic kidney disease.

Product Parameters

Why Cosperpharm?

When your hyperparathyroidism research or calcium homeostasis drug discovery program requires high-quality CaSR agonists, Cosperpharm delivers Evocalcet with the quality and consistency that pharmaceutical research demands.

Compound Integrity That Matters. The biological activity of Evocalcet is dependent on its ability to activate the calcium-sensing receptor. Our analytical release protocol for Evocalcet includes HPLC purity verification (≥99%), identity confirmation, and residual solvent analysis—ensuring your research is built on a reliable foundation.

Documentation That Supports Your Regulatory Submissions. Every shipment of Evocalcet includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery.

Flexible Supply for All Research Stages. Cosperpharm supplies Evocalcet from milligram-scale quantities for in vitro research to larger quantities for preclinical development. R&D samples ship within 5–7 business days.

Technical Expertise in Calcium Receptor Pharmacology. Our team can advise on solubility considerations, formulation strategies, and stability protocols for Evocalcet, ensuring your research proceeds efficiently.

Product Advantages

 Potent CaSR Agonist Activity

Evocalcet activates the calcium-sensing receptor with an EC₅₀ of 92.7 nM in hCaR-HEK293 cells, making it a potent tool for studying CaSR pharmacology.

 Orally Active Therapeutic Agent

Evocalcet is orally bioavailable and has demonstrated efficacy in animal models at doses as low as 0.3 mg/kg, supporting its development as a convenient oral therapy.

 Clinically Validated Mechanism

Evocalcet inhibits parathyroid hormone secretion in a dose-dependent manner and has progressed to Phase 3 clinical trials for hyperparathyroidism.

 High Purity for Research

Evocalcet is available with ≥99% HPLC purity and comprehensive characterization, ensuring reliable and reproducible results.

FAQ

Q1: What is Evocalcet used for?

A: Evocalcet is a CaSR agonist used in research on hyperparathyroidism and calcium homeostasis. It inhibits parathyroid hormone secretion from parathyroid gland cells.

Q2: What is the mechanism of action of Evocalcet?

A: Evocalcet activates the calcium-sensing receptor (CaSR) on parathyroid gland cells, mimicking the action of extracellular calcium and suppressing PTH secretion.

Contact Us

Ready to source Evocalcet for your calcium receptor research or hyperparathyroidism drug discovery program? Cosperpharm is your trusted partner for high-quality CaSR agonists. Contact us today to discuss your requirements and request a quote.